Quantinno Capital Management LP Decreases Position in DexCom, Inc. (NASDAQ:DXCM)

Quantinno Capital Management LP cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 55.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,571 shares of the medical device company's stock after selling 28,148 shares during the period. Quantinno Capital Management LP's holdings in DexCom were worth $1,513,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom during the 2nd quarter valued at approximately $25,000. Sachetta LLC grew its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after buying an additional 171 shares during the period. DT Investment Partners LLC increased its holdings in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after buying an additional 315 shares in the last quarter. Riverview Trust Co raised its position in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after acquiring an additional 232 shares during the period. Finally, ORG Partners LLC boosted its stake in shares of DexCom by 1,992.0% during the 2nd quarter. ORG Partners LLC now owns 523 shares of the medical device company's stock worth $59,000 after acquiring an additional 498 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DXCM shares. Wells Fargo & Company lifted their price target on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research note on Wednesday. Stifel Nicolaus boosted their price objective on DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, August 23rd. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Finally, Raymond James cut their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and an average price target of $98.00.

DexCom Trading Down 1.9 %

Shares of DexCom stock traded down $1.54 during trading hours on Thursday, hitting $78.93. The company's stock had a trading volume of 3,209,214 shares, compared to its average volume of 3,888,470. The stock has a market cap of $30.83 billion, a price-to-earnings ratio of 47.26, a P/E/G ratio of 2.38 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a fifty day moving average of $73.58 and a 200-day moving average of $84.99.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.